Cancelling mRNA studies is the highest irresponsibility
By Editors,
Nature
| 08. 15. 2025
The rest of the world is not following the US government’s dangerous path, and will stick with the technology that helped the world out of the COVID-19 pandemic.
A technology that played a key part in saving millions of lives during the COVID-19 pandemic1 should be feted to the skies. Instead, US health secretary Robert F. Kennedy Jr announced last week that the US federal government is terminating 22 grants worth nearly US$500 million for projects researching messenger RNA (mRNA) vaccines.
This is the technology that, in his first term (2017–21), US President Donald Trump included in Operation Warp Speed: the federal government’s $18-billion programme to procure COVID-19 vaccines for US populations in record time2. It is also the technology that is showing potential for treating cancers3, autoimmune diseases and inherited conditions such as sickle cell disease. But now, in a statement accompanying the grant cancellations, Kennedy stated that “these vaccines fail to protect effectively against upper respiratory infections like COVID and flu”. And in an article for The Washington Post, Jay Bhattacharya, director of the US National Institutes of Health, wrote that mRNA technology “failed to earn the public’s trust”, which fuelled vaccine hesitancy.
Shock and disbelief does not even begin...
Related Articles
By Rob Stein, NPR | 04.23.2026
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.
The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as...
By Alfonso Martinez Arias, Nicolas Rivron, and Naomi Moris, BioNews | 04.20.2026
By George Janes, BioNews | 04.20.2026
New regulations in sperm donation are being implemented by Belgium's Federal Agency for Medicines and Health Products (FAMHP), following revelations regarding the use of sperm carrying a cancer-causing mutation, and widespread breaches of donor limits.
In 2025, it...
By Sriparna Roy, Reuters | 04.23.2026
The U.S. Food and Drug Administration has approved Regeneron’s gene therapy for a rare genetic form of deafness, the company said on Thursday.
This approval, granted under the FDA’s new priority voucher program, marks the introduction of the first gene...